The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
Volker Heinemann
Honoraria - Merck; Roche
Research Funding - Merck
Other Remuneration - Merck; Roche
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Alexander Kiani
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Tobias Heintges
No relevant relationships to disclose
Juergen Lerchenmueller
No relevant relationships to disclose
Christoph Kahl
No relevant relationships to disclose
Gernot Seipelt
No relevant relationships to disclose
Frank Kullmann
No relevant relationships to disclose
Martina Stauch
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Joerg Hielscher
No relevant relationships to disclose
Michael Scholz
No relevant relationships to disclose
Sebastian Mueller
No relevant relationships to disclose
Britta Schaefer
No relevant relationships to disclose
Dominik Paul Modest
Honoraria - Merck
Other Remuneration - Merck
Andreas Jung
Honoraria - Merck
Research Funding - Merck
Other Remuneration - Merck
Sebastian Stintzing
Honoraria - Merck
Research Funding - Merck
Other Remuneration - Merck